These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24023332)

  • 1. Impact of chemotherapy with S-1 and oxaliplatin (SOX) in combination with molecular-targeting agents on colorectal liver metastases.
    Watanabe K; Kawahara H; Enomoto H; Toyama Y; Akiba T; Yanaga K
    Anticancer Res; 2013 Sep; 33(9):3941-6. PubMed ID: 24023332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
    Watanabe K; Kawahara H; Enomoto H; Toyama Y; Akiba T; Yanaga K
    Anticancer Res; 2013 Sep; 33(9):4029-32. PubMed ID: 24023346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of circulating tumor cells after preliminary chemotherapy for prediction of response to further anticancer therapy in patients with initially unresectable metastatic colorectal cancer.
    Neki K; Kawahara H; Watanabe K; Toyama Y; Akiba T; Yanaga K
    Anticancer Res; 2013 Apr; 33(4):1769-72. PubMed ID: 23564832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy.
    Arita J; Ono Y; Takahashi M; Inoue Y; Takahashi Y; Saiura A
    Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S390-7. PubMed ID: 24570378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002).
    Oki E; Emi Y; Miyamoto Y; Kabashima A; Higashi H; Ogata Y; Ikebe M; Saeki H; Tokunaga S; Shirabe K; Beppu T; Uchida S; Takatsuki M; Sakoda M; Eguchi S; Akagi Y; Kakeji Y; Baba H; Natsugoe S; Maehara Y;
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1067-74. PubMed ID: 26334293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of remnant liver metastases after resection of liver metastases from rectal cancer following treatment with 5-FU, L-OHP and CPT-11, with markedly effective treatment by cetuximab plus S-1].
    Takeuchi M; Ogata Y; Ishibashi N; Uchida S; Murakami N; Kibe S; Takahashi K; Yahara T; Shirouzu K
    Gan To Kagaku Ryoho; 2012 May; 39(5):843-6. PubMed ID: 22584346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of neoadjuvant chemotherapy with S-1 and oxaliplatin plus bevacizumab for colorectal liver metastasis (N-SOG 05 trial).
    Mukai T; Uehara K; Goto H; Hiramatsu K; Kobayashi S; Sakamoto E; Maeda A; Takeuchi E; Okada Y; Ebata T; Nagino M;
    Jpn J Clin Oncol; 2017 Jul; 47(7):597-603. PubMed ID: 28398493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer.
    Zhang ZD; Kong Y; Yang W; Zhang B; Zhang YL; Ma EM; Liu HX; Chen XB; Hua YW
    World J Surg Oncol; 2014 Apr; 12():115. PubMed ID: 24758484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
    Tomoda M; Kawahara H; Watanabe K; Enomoto H; Akiba T; Yanaga K
    Anticancer Res; 2014 Jan; 34(1):191-4. PubMed ID: 24403461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.
    Nakamura M; Yamada Y; Muro K; Takahashi K; Baba H; Sasaki Y; Komatsu Y; Satoh T; Mishima H; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
    Future Oncol; 2015; 11(10):1471-8. PubMed ID: 25963425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial Report of Phase II Study on Bi-weekly SOX plus Cetuximab Treatment for Wild-type K-RAS Advanced and Recurrent Colorectal Cancer.
    Ogawa M; Anan T; Suzuki T; Okuma M; Ichihara K; Hasegawa T; Yoshida K; Yanaga K
    Anticancer Res; 2016 May; 36(5):2505-11. PubMed ID: 27127165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical Response of Metastatic Colon Cancer to Chemotherapy with S-1 and Oxaliplatin - A Case Report].
    Morimoto T; Yata Y; Yonenaga Y; Hanaki K; Mise M; Higaside S; Kanda Y; Noda H
    Gan To Kagaku Ryoho; 2015 Jun; 42(6):743-5. PubMed ID: 26199249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study of S-1 and oxaliplatin(SOX) plus bevacizumab as first-line therapy in patients with unresectable colorectal cancer].
    Maruo H; Suzuki K; Ishikawa S; Murakami T; Higashi Y; Shoji T; Yamazaki M; Taniguchi M; Nishiyama R
    Gan To Kagaku Ryoho; 2014 Dec; 41(13):2583-6. PubMed ID: 25596052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Completely Responsive Multiple Liver Recurrence of Colon Cancer Treated Using Chemotherapy with Oral S-1 and Oxaliplatin Plus Bevacizumab : A Case Report.
    Kabashima A; Kimura K; Sanefuji K; Maekawa S
    Fukuoka Igaku Zasshi; 2017 Jan; 108(1):8-13. PubMed ID: 29226661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consequences of chemotherapy on resection of colorectal liver metastases.
    Pessaux P; Chenard MP; Bachellier P; Jaeck D
    J Visc Surg; 2010 Aug; 147(4):e193-201. PubMed ID: 20655821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
    Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
    Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
    Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Portal venous gas following chemotherapy for colorectal cancer liver metastasis.
    Zalinski S; Scatton O; Jacqmin S; Tacher V; Brézault C; Soubrane O
    Eur J Surg Oncol; 2009 May; 35(5):557-60. PubMed ID: 18950980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A Case of Synchronous Liver Metastasis of Ascending Colon Cancer with Pathological Complete Response to S-1/Oxaliplatin (SOX) and Bevacizumab].
    Tago T; Suzuki K; Nishida K; Maruyama T; Shimazaki J; Shimoda M; Suzuki S; Kou K; Morishita Y
    Gan To Kagaku Ryoho; 2018 May; 45(5):871-874. PubMed ID: 30026455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A Case Report of SOX Treatment for Primary Duodenal Carcinoma with Liver Metastasis].
    Yokota Y; Nagase H; Noguchi K; Hamabe A; Hirota M; Oshima K; Tanida T; Tomimaru Y; Kawase T; Morita S; Imamura H; Iwazawa T; Akagi K; Dono K
    Gan To Kagaku Ryoho; 2018 Apr; 45(4):715-717. PubMed ID: 29650845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.